1. School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom;
2. F. Hoffmann-La Roche Ltd, Basel, Switzerland;
3. Nuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom;
4. Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds, United Kingdom;
5. Southampton Cancer Research United Kingdom (CRUK)/National Institute of Health Research (NIHR) Experimental Cancer Medicines Centre, University of Southampton, Southampton, United Kingdom;
6. Southampton University Hospitals National Health Service (NHS) Foundation Trust, Southampton, United Kingdom;
7. Department of Medicine III, Ludwig-Maximilians University Hospital Munich, Munich, Germany;
8. Department of Pathology and Tumor Biology, Nagoya Graduate School of Medicine, Nagoya University, Nagoya, Japan;
9. Department of Hematopathology, University of Kiel, Kiel, Germany;
10. Department of Translational and Precision Medicine, Section of Hematology, Sapienza University, Rome, Italy;
11. Royal Marsden Hospital, London, United Kingdom;
12. BC Cancer Centre for Lymphoid Cancer;
13. Department of Medicine, University of British Columbia, Vancouver, BC, Canada;
14. 1st Department of Medicine, 1st Faculty of Medicine, Charles University General Hospital, Prague, Czech Republic;
15. Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy;
16. Genentech, Inc., South San Francisco, CA;
17. Roche Innovation Center Zurich, Roche Glycart AG, Schlieren, Switzerland; and
18. Antibody and Vaccine Group, Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, University of Southampton, Southampton, United Kingdom